Physician profile
Tyler B Moore
NPI 1215375928
$2,727.11
in general payments reported to CMS, 2019-2025
23 companies · $258 in 2025
The $258 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.55 · 2020: $111 · 2021: $338 · 2022: $1,529 · 2023: $286 · 2024: $142 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $686.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,626.72 | 2021-2023 | Tepezza |
| Bausch & Lomb Americas INC. | $159.68 | 2023-2025 | Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $129.85 | 2019-2025 | Cequa |
| Genmab U.S., INC. | $124.70 | 2023 | Tivdak |
| Kala Pharmaceuticals, INC. | $119.42 | 2021 | |
| Allergan, INC. | $102.69 | 2020-2021 | |
| Alcon Vision LLC | $74.59 | 2021-2025 | Rocklatan |
| Johnson & Johnson Surgical Vision, INC. | $42.85 | 2019-2021 | |
| Amgen INC. | $37.56 | 2024-2025 | Tepezza |
| Glaukos Corporation | $36.14 | 2021-2024 | Radius |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $29.55 | 2021 | |
| Rxsight INC | $28.69 | 2022-2023 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Dompe US, INC. | $27.17 | 2025 | Oxervate |
| Abiomed | $24.72 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $24.46 | 2024 | Xdemvy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23.56 | 2025 | |
| Sight Sciences, INC. | $22.82 | 2023 | Omni Surgical System |
| Harrow Eye, LLC | $21.62 | 2025 | Vevye |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Aerie Pharmaceuticals, INC. | $16.01 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.96 | 2019 | |
| Astellas Pharma US INC | $12.11 | 2021 | |
| New World Medical,INC. | $8.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.